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Coronary Side-Effect Potential of Current and Prospective
Antimigraine Drugs
Antoinette MaassenVanDenBrink, MSc; Marije Reekers, MSc; Willem A. Bax, MD, PhD;
Michel D. Ferrari, MD, PhD; Pramod R. Saxena, MD, PhD
Background—The antimigraine drugs ergotamine and sumatriptan may cause angina-like symptoms, possibly resulting
from coronary artery constriction. We compared the coronary vasoconstrictor potential of a number of current and
prospective antimigraine drugs (ergotamine, dihydroergotamine, methysergide and its metabolite methylergometrine,
sumatriptan, naratriptan, zolmitriptan, rizatriptan, avitriptan).
Methods and Results—Concentration-response curves to the antimigraine drugs were constructed in human isolated coronary
artery segments to obtain the maximum contractile response (Emax) and the concentration eliciting 50% of Emax (EC50). The
EC50 values were related to maximum plasma concentrations (Cmax) reported in patients, obtaining Cmax/EC50 ratios as an index
of coronary vasoconstriction occurring in the clinical setting. Furthermore, we studied the duration of contractile responses
after washout of the acutely acting antimigraine drugs to assess their disappearance from the receptor biophase. Compared
with sumatriptan, all drugs were more potent (lower EC50 values) in contracting the coronary artery but had similar efficacies
(Emax ,25% of K1-induced contraction). The Cmax of avitriptan was 7- to 11-fold higher than its EC50 value, whereas those
of the other drugs were ,40% of their respective EC50 values. The contractile responses to ergotamine and dihydroergotamine
persisted even after repeated washings, but those to the other drugs declined rapidly after washing.
Conclusions—All current and prospective antimigraine drugs contract the human coronary artery in vitro, but in view of
low efficacy, these drugs are unlikely to cause myocardial ischemia at therapeutic plasma concentrations in healthy
subjects. In patients with coronary artery disease, however, these drugs must remain contraindicated. The sustained
contraction by ergotamine and dihydroergotamine seems to be an important disadvantage compared with sumatriptan-
like drugs. (Circulation. 1998;98:25-30.)
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Sumatriptan, a 5-HT derivative with agonist activity at5-HT1B/1D receptors, is highly effective in aborting attacks of
migraine and cluster headache. The drug is generally well
tolerated. However, up to 15% of patients consistently report
chest symptoms, including chest pressure, tightness, and pain,
often mimicking angina pectoris.1–3 Although extracardiac
mechanisms have been invoked,4 chest symptoms may well be
caused by coronary vasoconstriction, which has been observed
after sumatriptan both in vivo5 and in vitro.6–8 In some cases, the
use of sumatriptan, like that of ergotamine,9–11 was even associ-
ated with myocardial infarction12,13 and cardiac arrest.14 “Second-
generation” sumatriptan-like antimigraine drugs are all aimed at,
in addition to achieving high efficacy and long duration of
action, avoiding coronary vasoconstrictor activity.15
The present study deals with 2 major issues in clinical
practice: (1) Do new antimigraine compounds cause less coro-
nary artery constriction than sumatriptan? and (2) Is sumatriptan
better than ergot derivatives in this respect? Obviously, these
questions cannot be easily answered by clinical trials. We
therefore employed a pharmacological approach using the hu-
man isolated coronary artery to determine the potency (sensitiv-
ity) and efficacy (magnitude) of the contractile responses to
sumatriptan and other current (ergotamine, dihydroergotamine,
methysergide, and its active metabolite methylergometrine16) as
well as new (naratriptan,17 zolmitriptan,18,19 rizatriptan,20 and
avitriptan21) antimigraine drugs. Results were related to the
respective Cmax reported in patients.
Because sumatriptan-induced contractions of coronary ar-
teries show substantial variability both within and between
studies,22,23 we used a “parallel” experimental design involv-
ing segments from the same coronary artery. These coronary
arteries were obtained from organ donors who died of causes
unrelated to cardiac diseases and therefore may potentially
represent the population treated with antimigraine drugs.
Methods
Preparation of Tissue
Right epicardial coronary arteries were obtained from 14 “heart
beating” organ donors (7 male, 7 female; age, 7 to 61 years) who
died of noncardiac disorders (11 of cerebrovascular accident, 3 of
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head trauma) ,24 hours before the tissue was taken to the labora-
tory. Hearts were provided by the Rotterdam Heart Valve Bank (Bio
Implant Services/Eurotransplant Foundation) after removal of the
aortic and pulmonary valves for transplantation purposes. The study
was approved by the joint Ethical Committee of the Erasmus
University Rotterdam and the University Hospital Rotterdam
“Dijkzigt.” The hearts were stored at 0°C to 4°C in a sterile
organ-protecting solution immediately after circulatory arrest. After
arrival in the laboratory, the right coronary artery was removed and
placed in a cold, oxygenated Krebs bicarbonate solution of the
following composition (mmol/L): NaCl 118, KCl 4.7, CaCl2 2.5,
MgSO4 1.2, KH2PO4 1.2, NaHCO2 25, and glucose 8.3; pH 7.4.
Vessels were cut into rings '4 mm long, suspended on stainless steel
hooks in 15-mL organ baths containing Krebs bicarbonate solution,
aerated with 95% O2/5% CO2, and maintained at 37°C. Vessel
segments containing distinct, macroscopically visible atherosclerotic
lesions were not used.
Experimental Protocol
After equilibration for at least 30 minutes and a wash every 15
minutes, changes in tissue force were recorded with a Harvard
isometric transducer. The vessel segments, stretched to a stable force
of '15 mN, were exposed to 30 mmol/L K1 twice, and the
functional integrity of the endothelium was verified by observation
of relaxation to substance P (1 nmol/L) after precontraction with
PGF2a (1 mmol/L). The tissue was washed and then exposed to
100 mmol/L K1. The data obtained with PGF2a, substance P, and
100 mmol/L K1 were averaged for each coronary artery. Subse-
quently, the vessel segments were washed again and, after a
30-minute equilibration period, 2 series of experiments were
performed.
Concentration-Response Curves and Relation With
Clinical Plasma Concentrations
In the first series of 9 experiments, a concentration-response curve
was constructed with the different compounds (ergotamine, dihydro-
ergotamine, methysergide, methylergometrine, sumatriptan,
naratriptan, rizatriptan, avitriptan, and zolmitriptan, as well as 5-HT
used as a marker). In some cases, concentration-response curves to
sumatriptan were obtained in duplicate, which were averaged and
regarded as one curve in further analysis. As described earlier in
detail,23 contractile responses were expressed as a percentage of the
contraction induced by 100 mmol/L K1 in the respective segments,
and the data were analyzed to obtain, in each case, values of Emax and
EC50. The Emax and EC50 values represent the efficacy and potency,
respectively, of a drug in eliciting a response (in this case, coronary
artery contraction). Thus, the lower the EC50 of a drug, the more
likely it is to cause coronary vasoconstriction at lower plasma
concentrations; the Emax is obviously only of importance when a drug
is present in high enough concentrations, as dictated by its potency.
To assess the capacity of various agonists to contract the human
coronary artery during clinical use in migraine, we calculated the
ratio between the reported Cmax after administration of clinically
effective doses (Table) and the EC50 value of the compounds in
contracting the human isolated coronary artery. Thus, a high Cmax/
EC50 ratio indicates that the plasma concentration of the drug is high
enough to contract the human coronary artery in the clinical
situation. The magnitude of this contraction will be dictated by the
Emax of the drug.
Duration of Action
In a second series of 5 experiments, the durations of action of the
acutely acting antimigraine drugs (ergotamine, dihydroergota-
mine, sumatriptan, naratriptan, rizatriptan, avitriptan, and zolmi-
triptan) were compared. For this purpose, contractions of coro-
nary artery segments were elicited with a single concentration of
these drugs (2 times EC50, as determined in the first series of
experiments), and the time to reach a stable contraction was
noted. The segments were then washed twice every 15 minutes,
and contractions remaining after each wash were noted for a total
period of 90 minutes.
Analysis of Data
Differences between EC50 and Emax values of sumatriptan and other
compounds as well as between contractions remaining after each
wash (every 15 minutes) were evaluated with Duncan’s new multiple
range test, once an ANOVA (randomized block design) had revealed
that the samples represented different populations. The Emax of the
compounds tested was correlated with the relaxant response to
substance P obtained in the individual coronary arteries (Pearson’s
Selected Abbreviations and Acronyms
Cmax 5 maximum plasma concentrations
EC50 5 concentration eliciting 50% of its own Emax
Emax 5 maximum effect, maximum contraction
5-HT 5 5-hydroxytryptamine
PGF2a 5 prostaglandin F2a
Emax (Expressed as % of Effect Caused by 100 mmol/L K1) and EC50 (nmol/L) Values in Human
Isolated Coronary Artery of 5-HT and Antimigraine Drugs, Together With Their Therapeutic
Doses and Cmax in Patients
EC50, nmol/L Emax, %K1
Dose, mg, and
Mode of Administration Cmax, nmol/L
5-HT 334699* 58.367.9* z z z z z z
Sumatriptan 8036197 14.062.9 100 PO2,42 142–1832,42
6 SC2,42 244–2612,42
Naratriptan 171636* 10.162.1 2.5, 5 PO43 38, 7143
Rizatriptan 448688* 10.162.7 10 PO44,45 74–9345
Zolmitriptan 476687* 11.862.5 2.5, 5 PO18,46 9, 1718
Avitriptan 89616* 7.761.8 75, 150 PO21 628, 94821
Ergotamine 1767* 20.563.7 2 PO 0.03–0.6247,48
0.5 IM47 1.38–3.2747
Dihydroergotamine 20610* 13.062.5 0.75, 1 IM/SC49 3, 449
Methysergide† 243698* 7.861.9 2 PO16 516
Methylergometrine† 46614* 13.463.5 2 methysergide PO16 1416
*Significantly different from sumatriptan (P,0.05).
†Not used in acute migraine therapy.
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correlation coefficient). Values of P#0.05 were considered to
indicate significant differences. All data in the text and illustrations
are presented as mean6SEM.
Results
Basic Properties of the Preparations: Effects of
Substance P and Potassium
All coronary artery segments, obtained from 14 hearts,
relaxed after substance P (1 nmol/L), the response amounting
to 6168% of the precontraction (3562 mN) to PGF2a
(1 mmol/L). Contraction to 100 mmol/L KCl was 4763 mN.
Concentration-Response Curves and Relation With
Substance P Response and Clinical
Plasma Concentrations
Concentration-response curves obtained in 9 coronary
arteries with the various compounds investigated are
shown in Figure 1, and the derived values of EC50 (nmol/L)
and Emax (% of contraction elicited by 100 mmol/L K1) are
shown in the Table. As reported earlier,22,23 the contractile
effect of sumatriptan on the isolated human coronary
artery showed a considerable variability; the EC50 and Emax
values ranged from 117 to 2042 nmol/L and 2.3% to 27.0%
of the response to 100 mmol/L K1, respectively. The EC50
values of all compounds, in particular ergotamine, dihy-
droergotamine, and methylergometrine, were significantly
lower than that of sumatriptan. The Emax of 5-HT was
significantly higher, but those of the other compounds did
not differ significantly from that of sumatriptan. However,
it may be noted that the Emax of other triptan derivatives is
about half that of ergotamine.
In the 9 hearts in which concentration-response curves to
the antimigraine agents were constructed, the correlation
between the Emax of the drugs and the coronary artery
relaxation to substance P (1 nmol/L) after precontraction with
PGF2a (1 mmol/L) was assessed. Pearson’s correlation coef-
ficient did not yield a significant P value with any of the
drugs (data not shown).
Figure 2 depicts the ratio between the reported plasma
Cmax obtained after administration of a clinically effective
dose (see Table) and the EC50 value of the compounds in
contracting the human isolated coronary artery. The data
show that, compared with that of 100 mg PO sumatriptan,
the Cmax/EC50 ratios of avitriptan (75 and 150 mg PO) were
higher, those of ergotamine (2 mg PO) and zolmitriptan
(2.5 and 5 mg PO) were lower, and those of the other
compounds (naratriptan, rizatriptan, and methysergide
measured as its active metabolite methylergometrine) were
in the same range. The ranges of Cmax/EC50 ratios obtained
with parenteral ergotamine (0.5 mg IM) and dihydroergot-
amine (1 mg SC) were not much different from that with
parenteral sumatriptan (6 mg SC).
Duration of Action
Contractions to a single concentration (2 times EC50) of the
acutely acting antimigraine drugs were elicited in 5 coro-
nary arteries. The peak stable contraction (% of
100 mmol/L K1) and the time required to reach the peak
contraction with the different compounds were as follows:
sumatriptan 1564% (362 minutes), naratriptan 1063%
(361 minutes), zolmitriptan 21615% (467 minutes),
rizatriptan 22616% (462 minutes), avitriptan 17612%
(561 minutes), ergotamine 2667% (24613 minutes), and
dihydroergotamine 27611% (18610 minutes). The effects
of repeated washings on the peak contractions elicited by
each drug are presented in Figure 3. The data show that the
contractile responses to ergotamine and dihydroergotamine
were sustained over the 90-minute period (P#0.05 versus
sumatriptan), whereas those to sumatriptan, naratriptan,
rizatriptan, avitriptan, and zolmitriptan nearly completely
disappeared after the second wash 30 minutes later.
Discussion
Human Coronary Artery Contraction In Vitro
As reported earlier in vitro6,8,24 and in vivo,25,26 5-HT induced
contraction of the human isolated coronary artery. 5-HT was
Figure 1. Concentration-response (expressed as % of response
to 100 mmol/L K1) curves in human isolated coronary arteries
(n59) obtained with current (left: ergotamine, ; dihydroergota-
mine, l; methysergide, f; and its metabolite methyler-
gometrine, ) and potential (right: zolmitriptan, M; rizatriptan, L;
naratriptan, ; and avitriptan, E) antimigraine drugs compared
with sumatriptan (F). Data are mean6SEM.
Figure 2. Relationship between reported Cmax concentration in
patients and EC50 values of various antimigraine compounds in
contracting human isolated coronary artery. Clinical doses and
mode of administration associated with Cmax values (see Table
for references) are indicated in each case, except methyler-
gometrine (measured after methysergide, 2 mg PO). When lower
and upper values are mentioned, they indicate reported range.
Note that a Cmax/EC50 ratio of 1 indicates that, if same condi-
tions were applicable in patients as in present in vitro experi-
ments, drug would elicit 50% of its maximum contraction of
coronary artery. In view of use of Cmax data from literature,
Cmax/EC50 ratios of different drugs were not subjected to statisti-
cal analysis.
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more efficacious (higher Emax value) than sumatriptan, be-
cause of a more prominent action mediated via 5-HT2
receptors.6,8,24,26
With respect to the antimigraine compounds, the results of
our study show that all drugs, but in particular ergotamine,
dihydroergotamine, and methylergometrine (metabolite of
methysergide16), were more potent (lower EC50 values) than
sumatriptan in contracting the human isolated coronary ar-
tery. Although the Emax of ergotamine tended to be somewhat
higher than that of sumatriptan, we observed no statistically
significant differences between Emax values of sumatriptan
and any of the other antimigraine drugs. Our findings are in
agreement with a recent report on zolmitriptan,19 but they
appear to be at variance with earlier studies claiming that
rizatriptan is only half as effective as sumatriptan in contract-
ing the human isolated coronary artery.27,28 Admittedly, data
obtained in human post mortem tissues can vary between
experiments because of a variety of factors, which are
difficult to discern. However, the coronary arteries used in
these studies27,28 were endothelium-denuded and obtained
from hearts from patients undergoing cardiac transplantation.
In contrast, the coronary arteries in the present experiments
were obtained from organ donors who died of noncardiac
causes, and the endothelium was not removed. Thus, our
population may better reflect the population likely to be
treated with 5-HT1B/1D receptor agonists.
Coronary Artery Contraction and Relaxation to
Substance P
It is suggested that relaxation to substance P is a measure of
the functional integrity of the endothelium and could be
related to underlying coronary artery disease.29,30 Because
there was no significant correlation between the Emax of the
compounds and relaxant response to substance P in the
coronary arteries used in the present investigation, it would
appear that the contractile effect of the antimigraine drugs is
not increased by underlying coronary artery disease. We
concede that the present study, with few data points at the
outer sides of the range of the relaxant response to substance
P, may not be particularly suitable for such an analysis.
However, even in a larger analysis (78 donor hearts), we did
not find an inverse but rather in fact a positive correlation
between the Emax of sumatriptan and the magnitude of
substance P relaxation in the human coronary artery.31
Coronary Artery Contraction at Therapeutic
Plasma Concentrations
We calculated the ratio between the clinically effective
plasma Cmax and EC50 values of the different antimigraine
compounds to estimate the degree of coronary vasoconstric-
tion to be expected during therapeutic use (see Figure 2).
Except for avitriptan, the plasma Cmax values of all drugs
tested remain ,40%, and in the case of zolmitriptan, ergot-
amine (2 mg PO), and methysergide (but note, not its
metabolite methylergometrine), even ,10% of their EC50
values. Thus, with the exception perhaps of avitriptan, ther-
apeutic doses of the antimigraine drugs investigated will
cause little coronary artery constriction in vivo. It was
recently shown with PET that sumatriptan did not affect
myocardial perfusion in healthy migraineurs at therapeutic
plasma concentrations.32 Even in the case of avitriptan, the
maximum coronary constriction (Emax '8% of 100 mmol/L
K1 response) will be barely perceptible and is unlikely to
affect coronary artery blood flow, which remains unchanged
until the arterial lumen is compromised by .80%.33 In
contrast, in patients with preexisting coronary artery lesions
who have only a limited coronary reserve,33 even a small
coronary artery contraction that may occur with plasma
concentrations encountered during clinical use could be
enough to cause myocardial ischemia. A similar phenomenon
may also be observed in patients with “variant” angina
pectoris, who have increased coronary artery sensitivity to
5-HT.26 It has been reported that the contractile effect of
sumatriptan on the human isolated coronary artery is poten-
tiated by thromboxane A223,34 and is inhibited by aspirin as
well as the thromboxane receptor antagonist SQ30741.23
Thus, exaggerated production of such substances locally may
augment coronary artery contractions to similar antimigraine
drugs in vivo.
Additional Factors Involved in Coronary Artery
Constriction in Patients
Other factors involved in the contraction of coronary arteries
in vivo are slow diffusion from the receptor biophase, plasma
protein binding, and the formation of active metabolites.
Slow diffusion from the receptor biophase, which has been
reported for ergot derivatives,35 is in accordance with our
findings concerning the sustained response to both ergota-
mine and dihydroergotamine despite repeated washings (Fig-
ure 3). In the clinical situation, it is also known that the effects
of ergotamine and dihydroergotamine sustain much longer
than is to be expected from their plasma concentration
profiles.35–37 Indeed, substernal chest pain and discomfort
suggestive of myocardial infarction have repeatedly been
described with ergot preparations, particularly ergotamine.10,38
Dihydroergotamine,39 methysergide,16 and possibly ergota-
mine38 form active metabolites, which, as is clearly the case
with methysergide (see results with methylergometrine), may
also cause coronary artery constriction. Sumatriptan does not
have active metabolites,40 but zolmitriptan forms an
N-desmethyl derivative, which is approximately twice as
Figure 3. Effect of repeated washings (3 times every 15 min-
utes) on contractions of human coronary arteries (n55) elicited
by acutely acting antimigraine drugs (ergotamine, ; dihydroer-
gotamine, l; sumatriptan, F; zolmitriptan, M; rizatriptan, L;
naratriptan, ; and avitriptan, E). All drugs were administered
once at a concentration 2 times their EC50 (see Table). Data are
mean6SEM.
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potent as the parent compound in causing vasoconstriction.41
We do not know whether active metabolites are formed by
avitriptan, naratriptan, or rizatriptan. However, in view of its
structural similarity to zolmitriptan, rizatriptan may be ex-
pected to form an N-desmethyl derivative, which may be
pharmacologically active. Except for sumatriptan (14% to
21% plasma protein binding40), we do not know the extent of
plasma protein binding of the other drugs.
In conclusion, all current and prospective antimigraine
drugs investigated contract the human coronary artery in
vitro. Apart from avitriptan, therapeutic plasma concentra-
tions of the drugs do not reach levels likely to cause
myocardial ischemia in individuals with normal coronary
circulation. However, like sumatriptan, all antimigraine com-
pounds investigated, including the newer drugs, must remain
contraindicated in patients with coronary artery disease. The
sustained coronary artery contraction induced by ergotamine
and dihydroergotamine is an important disadvantage com-
pared with the sumatriptan-like drugs.
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